-
Je něco špatně v tomto záznamu ?
New perspectives of 19F MAS NMR in the characterization of amorphous forms of atorvastatin in dosage formulations
J. Brus, M. Urbanova, I. Sedenkova, H. Brusova,
Jazyk angličtina Země Nizozemsko
Typ dokumentu srovnávací studie, časopisecké články, práce podpořená grantem
- MeSH
- časové faktory MeSH
- faktorová analýza statistická MeSH
- fluor chemie MeSH
- krystalizace MeSH
- kyseliny heptylové chemie MeSH
- magnetická rezonanční spektroskopie metody MeSH
- prášková difrakce MeSH
- pyrroly chemie MeSH
- reprodukovatelnost výsledků MeSH
- spektroskopie infračervená s Fourierovou transformací metody MeSH
- Publikační typ
- časopisecké články MeSH
- práce podpořená grantem MeSH
- srovnávací studie MeSH
Despite recent advances in solid-state NMR spectroscopy, the structural characterization of amorphous active pharmaceutical ingredients (APIs) in solid dosage forms continues to be a monumental challenge. To circumvent complications following from low concentrations of APIs in tablet formulations, we propose a new time-saving procedure based on chemometric approach: factor analysis of (19)F MAS NMR spectra. Capability of the proposed method is demonstrated on atorvastatin--a typical representative of fluorinated pharmaceutical substances exhibiting extensive polymorphism. Applying the factor analysis on the recorded (19)F MAS NMR spectra, unique parameters for every sample were derived. In this way every solid form of atorvastatin was characterized and clearly distinguishable even among various amorphous and disordered forms. The proposed method was also found to be suitable for both qualitative and quantitative analysis of mixtures of various forms of atorvastatin. Reliability of the proposed method was extensively examined by comparing the obtained results with other experimental techniques such as (13)C CP/MAS NMR, FTIR and XRPD. As highly linear correlations between the sets of parameters obtained from different experimental data were found, the perspectives of the applied comparative factor analysis to obtain detail structural view on variability of amorphous forms of atorvastatin are also discussed. Although the reported method was tested on atorvastatin, authors expect wider application for any fluorinated compound to give the routine, fast and reliable characterization of amorphous forms of APIs in drug products even at low concentrations (1-5%). Bear in mind that 20-25% of currently developed pharmaceuticals contain at least one fluorine atom in the molecule.
Citace poskytuje Crossref.org
- 000
- 00000naa a2200000 a 4500
- 001
- bmc12027781
- 003
- CZ-PrNML
- 005
- 20121211195114.0
- 007
- ta
- 008
- 120817e20110226ne f 000 0#eng||
- 009
- AR
- 024 7_
- $a 10.1016/j.ijpharm.2011.02.030 $2 doi
- 035 __
- $a (PubMed)21356299
- 040 __
- $a ABA008 $b cze $d ABA008 $e AACR2
- 041 0_
- $a eng
- 044 __
- $a ne
- 100 1_
- $a Brus, Jiří, $d 1970- $7 jo2011640489 $u Institute of Macromolecular Chemistry, Academy of Sciences of the Czech Republic, Heyrovsky Sq. 2, 162 06 Prague 6, Czech Republic. brus@imc.cas.cz
- 245 10
- $a New perspectives of 19F MAS NMR in the characterization of amorphous forms of atorvastatin in dosage formulations / $c J. Brus, M. Urbanova, I. Sedenkova, H. Brusova,
- 520 9_
- $a Despite recent advances in solid-state NMR spectroscopy, the structural characterization of amorphous active pharmaceutical ingredients (APIs) in solid dosage forms continues to be a monumental challenge. To circumvent complications following from low concentrations of APIs in tablet formulations, we propose a new time-saving procedure based on chemometric approach: factor analysis of (19)F MAS NMR spectra. Capability of the proposed method is demonstrated on atorvastatin--a typical representative of fluorinated pharmaceutical substances exhibiting extensive polymorphism. Applying the factor analysis on the recorded (19)F MAS NMR spectra, unique parameters for every sample were derived. In this way every solid form of atorvastatin was characterized and clearly distinguishable even among various amorphous and disordered forms. The proposed method was also found to be suitable for both qualitative and quantitative analysis of mixtures of various forms of atorvastatin. Reliability of the proposed method was extensively examined by comparing the obtained results with other experimental techniques such as (13)C CP/MAS NMR, FTIR and XRPD. As highly linear correlations between the sets of parameters obtained from different experimental data were found, the perspectives of the applied comparative factor analysis to obtain detail structural view on variability of amorphous forms of atorvastatin are also discussed. Although the reported method was tested on atorvastatin, authors expect wider application for any fluorinated compound to give the routine, fast and reliable characterization of amorphous forms of APIs in drug products even at low concentrations (1-5%). Bear in mind that 20-25% of currently developed pharmaceuticals contain at least one fluorine atom in the molecule.
- 650 _2
- $a krystalizace $7 D003460
- 650 _2
- $a faktorová analýza statistická $7 D005163
- 650 _2
- $a fluor $x chemie $7 D005461
- 650 _2
- $a kyseliny heptylové $x chemie $7 D006538
- 650 _2
- $a magnetická rezonanční spektroskopie $x metody $7 D009682
- 650 _2
- $a prášková difrakce $7 D033362
- 650 _2
- $a pyrroly $x chemie $7 D011758
- 650 _2
- $a reprodukovatelnost výsledků $7 D015203
- 650 _2
- $a spektroskopie infračervená s Fourierovou transformací $x metody $7 D017550
- 650 _2
- $a časové faktory $7 D013997
- 655 _2
- $a srovnávací studie $7 D003160
- 655 _2
- $a časopisecké články $7 D016428
- 655 _2
- $a práce podpořená grantem $7 D013485
- 700 1_
- $a Urbanová, Martina
- 700 1_
- $a Sedenkova, Ivana
- 700 1_
- $a Brusová, Hana
- 773 0_
- $w MED00002359 $t International journal of pharmaceutics $x 1873-3476 $g Roč. 409, č. 1-2 (20110226), s. 62-74
- 856 41
- $u https://pubmed.ncbi.nlm.nih.gov/21356299 $y Pubmed
- 910 __
- $a ABA008 $b sig $c sign $y m
- 990 __
- $a 20120817 $b ABA008
- 991 __
- $a 20121211195157 $b ABA008
- 999 __
- $a ok $b bmc $g 949823 $s 785127
- BAS __
- $a 3
- BAS __
- $a PreBMC
- BMC __
- $a 2011 $b 409 $c 1-2 $d 62-74 $e 20110226 $i 1873-3476 $m International journal of pharmaceutics $n Int. j. pharm. $x MED00002359
- LZP __
- $a Pubmed-20120817/11/03